Connect with us

Life Sciences

New Journal of Pharmaceutical Analysis articles showcase innovative approaches for diagnostics and drug screening and evaluation

Cancer and cardiovascular diseases (CVDs) continue to be two of the biggest challenges facing modern medicine. Developing better diagnostic procedures,…

Published

on

This article was originally published by BioEngineering

Cancer and cardiovascular diseases (CVDs) continue to be two of the biggest challenges facing modern medicine. Developing better diagnostic procedures, as well as drug screening and assessment techniques, are crucial steps in the path to more effective treatments. The latest issue of the JPA features three articles on cutting-edge research in these directions.

Highlights of the Journal of Pharmaceutical Analysis April 2023 issue

Credit: Journal of Pharmaceutical Analysis

Cancer and cardiovascular diseases (CVDs) continue to be two of the biggest challenges facing modern medicine. Developing better diagnostic procedures, as well as drug screening and assessment techniques, are crucial steps in the path to more effective treatments. The latest issue of the JPA features three articles on cutting-edge research in these directions.

The first study reports a novel non-invasive diagnostic tool to detect gastrointestinal tumors and was available online in February 2023 and published in Volume 13, Issue 4 of the journal in April 2023. This Good Manufacturing Practices-compliant probe is based on TST001, a man-made antibody that targets the protein CLDN18.2, which is overexpressed in various types of cancers. By labelling this antibody with radioactive zirconium, the researchers could quickly and non-invasively measure the expression of CLDN18.2 in both cancer cell lines and in vivo mouse models.

Currently, CLDN18.2 is measured using immunohistochemistry, which is invasive and limited in scope. This new approach, however, represents a great advantage over the conventional method. Talking about the potential applications of their research, author Hua Zhu, remarks, “With the increasing popularity of positron emission tomography and computed tomography equipment, we expect our probe to be used for screening patients with higher potential benefit from therapy, localizing systemic lesions, and evaluating the efficacy of novel drugs.

The second article by Cheng et al. discusses the pharmacological effects of two precious traditional Chinese medicinal herbs: Panax ginseng (PG) and Panax notoginseng (PN). The team developed a novel RNA sequencing-based, low-cost workflow called ‘TCM-seq’, which enabled them to simultaneously measure the effects of different doses of PG and PN components on multiple cell lines at the RNA or transcriptome level, greatly reducing experimental times and costs. Their findings indicated that saponins found in PG and PN may regulate genes involved in CVD and coagulation, respectively. Our study proposes a new paradigm to comprehensively explore the differences in the mechanisms of action of Chinese medicines based on transcriptome readout,” the corresponding author Xiaohui Fan remarks.

In the third study, researchers show how the mechanical and physiological properties of a cell can be useful for evaluating drug efficacy. To this end, they mechanically stimulated breast cancer and kidney cells, and developed a mathematical framework to record the change in their mechanical (viscosity and elasticity) properties in response to the drugs doxorubicin and paclitaxel. The technique can be used in cell cultures started form tumor samples at the single-cell level. According to the corresponding author Wenxue Wang, “Applying our approach for susceptibility testing before clinical chemotherapy will help improve the therapeutic effect of drugs and promote the advancement of personalized medicine”.

Overall, these studies will pave the way to a deeper understanding of complex diseases like cancer and provide new techniques to discover, develop, and analyze the efficacy of treatments.

***

Reference

DOI:  https://doi.org/10.1016/j.jpha.2023.02.011

Authors: Yan Chen1,2, Xingguo Hou2, Dapeng Li1,2, Jin Ding2, Jiayue Liu2, Zilei Wang2,3, Fei Teng4, Hongjun Li4, Fan Zhang4, Yi Gu4, Steven Yu4, Xueming Qian4, Zhi Yang1,2,5, and Hua Zhu1,2,5

Affiliations:

1Guizhou University Medicine College

bThe Ministry of Education Key Laboratory of Carcinogenesis and Translational Research; NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute

3Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University

4Suzhou Transcenta Therapeutics Co., Ltd.

5Institute of Biomedical Engineering, Peking University Shenzhen Graduate School






personalized medicine


Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending